OBJECTIVE: Retrospective study to investigate levels of components of the urokinase-type plasminogen activator (uPA) system in patients with chronic obstructive pulmonary disease (COPD). METHODS: Peripheral lung tissue was obtained from patients who underwent surgical resection for benign lung diseases: 16 patients with COPD, 10 controls without lung function impairment who were smokers, and 10 controls without lung function impairment who were nonsmokers.
Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, and is responsible for nearly 2 million deaths in China each year. 1 The high prevalence of smoking and biomass fuel use are major contributors to the high incidence of COPD in China, and Y Zhang, W Xiao, Y Jiang et al. Urokinase-type plasminogen activator in COPD this disease is associated with major physical, emotional and economic burdens. 2 Despite intensive research on the development and progression of airflow limitation, the precise mechanisms of COPD remain unclear.
The main components of the urokinasetype plasminogen activator (uPA) system include the local serine protease uPA, uPAspecific cell surface receptor (uPAR) and plasminogen activator inhibitor (PAI)-1. After uPA is activated by plasmin cleavage of pro-uPA 3 it converts inactive plasminogen into plasmin, which is a key fibrinolytic enzyme that breaks down many extracellular matrix and basement membrane molecules. 4 uPAR is a 270 amino acid glycosyl-phosphatidylinositol anchored protein that plays an important role in the localization of uPA to the cell surface. 5 PAI-1 regulates the turnover of matrix mainly by mediating the balance between proteolysis and antiproteolysis. 6, 7 The uPA system is also involved in innate immunity, cell migration, recruitment and adhesion, mitogenesis and inflammation after tissue injury. 8 Activation of the uPA system has been demonstrated in several models of airway inflammation and lung disease including adult respiratory distress syndrome, 9 idiopathic pulmonary fibrosis 10 and asthma. 11 − 13 Levels of uPAR and PAI-1 were significantly elevated in the induced sputum of COPD patients, in one study; 14 this elevation was highly correlated with lung function and interleukin-8 levels. 14 uPA and uPAR have been suggested as potential targets for COPD treatment, 15 but their patterns of expression in lung tissue from patients with COPD have not been established.
The aim of this study was to investigate the levels of the various components of the uPA system in peripheral lung tissue from COPD patients, using immunohistochemistry. The relationships between these proteins and emphysema, and the deposition of small airway collagen, were also investigated.
Patients and methods

STUDY POPULATION
Sequential patients who underwent surgical resection for benign lung disease (such as granulomatous inflammation, inflammatory pseudotumours, pulmonary bullae or haematomas) at Qilu Hospital, Shandong University, Jinan, China, between January 2010 and May 2011 were enrolled in this retrospective study.
Pulmonary function was measured before surgery using a spirometer (MasterScreen Series; Jaeger, Hoechberg, Germany). Forced expiratory volume in 1 s (FEV 1 ) and FEV 1 /forced vital capacity (FVC) ratio were recorded before and 15 min after the inhalation of 200 mg salbutamol (reversibility test). 16 The diagnosis of COPD was made according to the guidelines of the Global Initiative for Chronic Obstructive Lung Disease. 17 Patients who required surgery in both lungs, and those with severe exacerbation of COPD or a lower respiratory tract infection within the previous 4 weeks, were excluded from the study.
Participants were categorized into three groups: patients with COPD; control smokers without lung function impairment; control nonsmokers (who had never smoked) without lung function impairment. 
EVALUATION OF EMPHYSEMA
Computed tomography (CT) images were obtained using a SOMATOM ® Sensation 16 CT scanner (Siemens, Erlangen, Germany) or a General Electric LightSpeed ® 16 scanner (GE Healthcare Biosciences, Piscataway, NJ, USA). The percentage of low attenuation areas (LAA%) in the lung that did not undergo surgery was used as a quantitative index of emphysema. 18 
IMMUNOHISTOCHEMISTRY
Between three and six randomly selected tissue samples were obtained from the subpleural parenchyma (> 5 cm away from the diseased area of the lung). Samples were fixed in 4% formaldehyde, dehydrated in ethanol, embedded in paraffin wax and cut into 5-µm sections. Tissue sections were subjected to antigen retrieval by heating in a microwave oven (on high power for 10 min followed by medium power for 15 min) in 0.01 M citrate buffer, pH 6.0. Slides were incubated with primary antibodies against uPA (rabbit antihuman, 1 : 80 dilution, American Diagnostica Inc., Stamford, CT, USA), uPAR (mouse antihuman, 1 : 80 dilution, Abcam ® , Carlsbad, CA, USA) and PAI-1 (mouse antihuman, 1 : 80 dilution, American Diagnostica Inc.) in standard avidin-biotinylated peroxidase complex immunohistochemistry, as described in previous studies. 14, 20 The appropriate peroxidase conjugated secondary antibody (either goat antirabbit immunoglobulin G or goat antimouse immunoglobulin G; both from Dako, Kyoto, Japan) were used at 1 : 1000 dilution. For negative controls, the primary antibody was replaced with 0.01 M phosphate buffered saline, pH 7.2.
SIRIUS RED STAINING
Sirius red polarization microscopy was used to detect interstitial collagen. 21 The staining procedure was performed as described previously 22 using tissue samples prepared as detailed above. Collagen types I and III were identified by appearing red or yellow, respectively, under polarized light. The amount of total collagen per sample was considered to be indicative of the amount of small airway fibrosis present.
QUANTIFICATION OF STAINING
All staining was evaluated in four randomly chosen fields per slide at × 400 magnification using an Olympus IX81 light microscope (Olympus, Tokyo, Japan). Image-Pro ® Plus 5.0 software (Media Cybernetics, Silver Spring, MD, USA) was used to determine mean staining density in the small airway epithelia and the total area of Sirius red staining in pixels (red or yellow staining). Immunostaining in alveolar wall cells and macrophages was evaluated by two pathologists who did not have access to the clinical data. Alveolar wall cells were quantified as the number of cells/mm 2 and macrophages were quantified as the ratio of the number of stained macrophages to the total number of macrophages, expressed as a percentage, in order to minimize the effect of tissue volume differences. The mean of the data from the two pathologists was calculated. 
STATISTICAL ANALYSES
Results
The study enrolled 36 participants who underwent surgical resection for benign lung diseases: 16 patients with COPD, 10 controls who were smokers without lung function impairment and 10 controls who were nonsmokers without lung function impairment. Demographic and clinical characteristics of the study subjects are shown in Table 1 . Patients with COPD had significantly lower FEV 1 and FEV 1 /FVC and significantly higher emphysema scores (LAA%) than controls (P < 0.05 for all comparisons). There was no significant difference between control smokers and patients with COPD in the number of cigarettes smoked per year (Table 1) .
Staining for uPA or uPAR was significantly elevated in the small airway epithelia of patients with COPD compared with controls (uPA, P < 0.01 for both comparisons; uPAR, P < 0.05 for both comparisons; Figs 1A, 1B , 2A, 2B, Table 2 ). In contrast, PAI-1 staining was significantly reduced in the small airway epithelia of patients with COPD compared with controls (P < 0.05 for both comparisons; Table 2 ; Figs 3A, 3B [comparison of smokers]).
There were significantly more uPA-and uPAR-positive alveolar wall cells in patients with COPD compared with controls (uPA, P < 0.01 for both comparisons; uPAR, P < 0.05 for both comparisons; Figs 1C, 1D, 2C, 2D, Table  2 ). There were significantly fewer PAI-1- Table 2 ).
TABLE 1: Demographic and clinical characteristics of patients with chronic obstructive pulmonary disease (COPD) and controls (smokers and nonsmokers with benign lung disease without lung function impairment) who participated in the present study to examine the relationship between COPD and components of the urokinase-type plasminogen activator system
Patients with COPD had significantly higher percentages of uPA, uPAR and PAI-1positive macrophages than controls (uPA and uPAR, P < 0.001; PAI-1, P < 0.01; Table 2 ; Fig 3C, 3D [comparison of smokers] ). The total area of Sirius red-positive staining for interstitial collagen was significantly higher in patients with COPD than in smoker and nonsmoker controls (P < 0.05 for both comparisons; Table 2 ).
Across the study population, multiple inverse correlations were observed between FEV 1 and uPA, uPAR and PAI-1 (Table 3) . There was a significant positive correlation between the amount of collagen and uPA staining density in small airway epithelia (r = 0.4187, P = 0.0011) as well as the percentage of PAI-1-positive macrophages (r = 0.4025, P = 0.0149). There was also a significant positive correlation between the degree of emphysema (LAA%) and the percentage of uPA-positive macrophages (r = 0.4026, P = 0.0149).
Discussion
The present study provided in vivo evidence for the role of the uPA system in COPD: there were multiple correlations between uPA system components and COPD pathology.
Proteolysis mediated by the uPA system is tightly controlled under normal physiological conditions, but may be deregulated in several c Ratio of the number of positive macrophages to the total number of macrophages expressed as a percentage. d Sirius red-positive staining area (× 10 5 pixels; four randomly chosen fields per slide at × 400 magnification). *P < 0.05, **P < 0.01 and ***P < 0.001 compared with both control smokers and control nonsmokers; Mann-Whitney U-test. Urokinase-type plasminogen activator in COPD diseases in which inflammation and tissue repair are involved. 8 Regulation of the activity of metalloproteinase 23, 24 in extracellular matrix degradation, which is an essential component of COPD, 25 − 30 is also mediated by uPA-uPAR binding. Elevated levels of uPA were detected in small airway epithelia, alveolar wall cells and pulmonary macrophages in patients with COPD in the present study. uPA staining was significantly correlated with FEV 1 , small airway fibrosis and the degree of emphysema: a finding that is consistent with other reports. 15, 31 Taken together, these findings support the hypothesis that an increase in uPA leads to the destruction of small airways and alveolar cells.
The importance of the uPA system in autoimmunity has been reported, 32, 33 with one study in mice suggesting that autoimmunity was more important than acquired immunity in COPD. 34 This may, therefore, be another mechanism by which uPA participates in COPD. It is possible that the fibrinolytic activity of epithelial uPA plays an important role in COPD. 35 In addition to functioning as a protease receptor, uPAR-mediated intracellular signalling regulates cell adhesion, migration, differentiation and proliferation. 36 uPARdependent cell recruitment is sometimes independent of uPA, 37, 38 and mice deficient in uPA or uPAR are susceptible to different pathogens, 39, 40 indicating that uPA and uPAR may function independently in different processes. uPAR is required to mount effective innate and adaptive immune responses and is, therefore, viewed as a proinflammatory agent. The elevated levels of uPAR in macrophages and structural cells, which were observed in patients with COPD in the present study, indicate that uPAR may play a key role in inflammation; inflammation is an important characteristic of COPD.
Small airway disease (obstructive bronchiolitis) is a major pathophysiological feature of COPD. 17, 41 A prominent aspect of small airway remodelling is peribronchial fibrosis, which may decrease airway elasticity and reduce the response to bronchodilatating agents. 41 Peribronchial fibrosis may also disrupt alveolar attachments to the airway, predisposing the airway to expiratory closure. 42 PAI-1 -the principle inhibitor of uPA -promotes collagen deposition and fibrosis, and restrains the activity of both uPA and matrix metalloproteinases. 11, 13 The present study revealed that the percentage of PAI-1positive macrophages in COPD patients was much higher than that in controls, which is consistent with reported increases in PAI-1 in induced sputum from COPD patients. 14 The present study also found that the percentage of PAI-1-positive macrophages was significantly correlated with the deposition of collagen, indicating that PAI-1 plays a key role in COPD small airway fibrosis, possibly via an inflammatory response. In addition, the reduction in PAI-1 in airway epithelia and alveolar wall cells in patients with COPD in the present study implies an imbalance between elastase and antielastase in alveolar destruction.
Components of the uPA system, including uPA, uPAR and PAI-1, are highly involved in the pathogenesis of lung cancer, which is a frequent comorbidity in COPD patients. 43 Overexpression of uPA system components is correlated with lung cancer progression, metastasis and poor prognosis. 44 The present study collected lung tissue from patients with benign lung diseases only, in order to exclude the effects of lung cancer on the uPA system. The relatively small number of subjects in this study prevented division of the patients with COPD into subgroups of different severity. Further investigations with larger sample sizes are required to elucidate the mechanisms of the uPA system in COPD.
In conclusion, this study demonstrates that the components of the uPA system are present at different levels in lung tissue from patients with COPD compared with control smokers and nonsmokers. There are significant correlations between the levels of uPA system components and lung function, and the degree of small airway fibrosis and emphysema. The uPA system may play a crucial role in the development of COPD, possibly by participating in both inflammation and tissue remodelling, including parenchymal destruction and small airway fibrosis.
